Genentech Haemophilia therapy gets FDA breakthrough designation
September 4, 2015Research and Development, Sales and Marketing Genentech, Roche, haemophilia a
Roche subsidiary Genentech has been granted FDA breakthrough therapy designation for its ACE910 (RG6013, RO5534262) haemophilia A therapy. The designation …
Companies braced for new round of cancer cuts
September 4, 2015Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NHS England, cuts
Several treatments that extend the lives of people with cancer are expected to be removed from the Cancer Drugs Fund …
Novartis blood cancer drug Farydak receives EU approval
September 4, 2015Sales and Marketing Cancer, European Commission, Farydak, Novartis, multiple myeloma, myeloma, panobinostat
The European Commission has approved Novartis’s Farydak, in combination with Velcade and dexamethasone, for the treatment of adult patients with …
AstraZeneca lung cancer drug clears UK market access hurdle
September 4, 2015Sales and Marketing AZD9291, AstraZeneca, Early Access to Medicines Scheme, MHRA, NSCLC, eams, lung cancer, non-small cell lung cancer
Follow @Pharmafocus
Novartis heart failure drug available via EAMS
September 3, 2015Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan
Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …
Health ministers vow NHS tech revolution
September 3, 2015Medical Communications Jeremy Hunt, NHS, data protection, digital technology, george freeman
UK health ministers have challenged the NHS to fully utilise technology, to empower patients to manage their own healthcare needs.Their …
How ‘deep reading’ of the scientific literature will benefit pharma
September 3, 2015Research and Development Big Data, Cancer, Data Mining, R&D, literature search, oncology
The US Defense Advanced Research Projects Agency (DARPA)’s $45 million ‘Big Mechanism’ initiative has an ambitious aim.It promises to “leapfrog …
NICE pushes biosimilars in rheumatoid arthritis guidance
September 3, 2015Sales and Marketing
NICE has published final draft guidance confirming its recommended treatment options for rheumatoid arthritis. For the first time copycat, or …
Sandoz launches first US biosimilar
September 3, 2015Manufacturing and Production, Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, biosimilars, filgrastim
Sandoz, the generics arm of the pharma giants Novartis, has become the first company to launch a biosimilar product in …
Shire appoints Sara Mathew to board of directors
September 2, 2015Manufacturing and Production, Research and Development, Sales and Marketing Sara Mathew, Shire
Shire has appointed Sara Mathew to its board of directors as a non-executive director.Mathew will also be a member of …
Pharma ‘spends €40m to sway EU politicians’
September 2, 2015Medical Communications EU, European Commission, TTIP, drug policy, lobbying, transparency
The pharma industry has excessive power over EU decision-makers and spends €40 million a year to influence EU drug policy, …
Amgen and Novartis partner on Alzheimer’s and migraine treatments
September 2, 2015Research and Development Alzheimer's disease, Amgen, Novartis, migraine, neurology, neuroscience
Amgen and Novartis have announced a global collaboration to develop neuroscience treatments in Alzheimer’s disease and migraine. The companies plan …
Two Novartis drugs get first in class EU approvals
September 2, 2015Research and Development, Sales and Marketing Novartis
The European Commission has approved Revolade for severe aplastic anaemia, and the combination of Tafinlar and Mekinist for patients with …
Bayer backs safety of Xarelto after real-world data study
September 2, 2015Research and Development Bayer, ESC, European Society of Cardiology, Xarelto, anticoagulants, atrial fibrillation, real-word evidence, rivaroxaban
Around 96 in every 100 people treated with Bayer’s anticoagulant Xarelto do not experience any major bleeding, related side effects …
Sanofi joins Google in diabetes tech push
September 1, 2015Medical Communications Andy Conrad, Google life sciences, Sanofi, Type 1 diabetes, diabetes, google, type 2 diabetes
Google is continuing its work in diabetes, by teaming up with pharma giants Sanofi to create new digital technologies and …
Standardising the pharma benefit-risk assessment process
September 1, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, FDA, benefit-risk analysis, pharmacoepidemiology, pharmacovigilance
Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view …
Alexion scores double EU approval
September 1, 2015Manufacturing and Production, Sales and Marketing Alexion, EC, European Commission, Kanuma, Strensiq, asfotase alfa, sebelipase alfa, ultra rare disease, ultra-rare disease
Two treatments developed by ultra-rare disease specialists Alexion Pharmaceuticals are now approved for use in Europe. The European Commission approved …
Bristol-Myers Squibb makes big pharma deals
September 1, 2015Manufacturing and Production BMS, Bristol-Myers Squibb, PRM-151, Promedior, QIMR, fibrosis, idiopathic pulmonary fibrosis, immuno-oncology, myelofibrosis
Bristol-Myers Squibb is flexing its muscles in respiratory disease, by signing a deal to acquire the exclusive right to acquire …
FDA issues gliptin joint pain warning
September 1, 2015Manufacturing and Production DPP-4 inhibitors, ESC, FDA, TECOS, adverse effects, drug safety, gliptins, safety alert, safety warning
The FDA has issued a safety alert, warning of joint pain caused by the gliptins, a common class of drugs …
NHS approves electronic consent technology in clinical trials
August 28, 2015Medical Communications, Research and Development Mytrus, NHS, clinical trials, digital health technology, electronic informed consent
Clinical technology and services company Mytrus has announced that its software platform for electronic informed consent has received approval for …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
